| | | TOP STORY |
TLR7 Induces Anergy in Human CD4+ T Cells
Scientists found that engagement of Toll-like receptor (TLR)7 in CD4+ T cells induced intracellular calcium flux with activation of an anergic gene-expression program dependent on the transcription factor NFATc2, as well as unresponsiveness of T cells. [Nat Immunol] Abstract
|
|
| | | PUBLICATIONS (Ranked by impact factor of the journal) |
Cigarette Smoking Impairs Human Pulmonary Immunity to Mycobacterium tuberculosis
Researchers compared the functional impairment, seen in human alveolar macrophages from non-smokers, smokers and ex-smokers, after infection with M. tuberculosis. [Am J Respir Crit Care Med]
Abstract
|
Press Release
Fc Gamma Receptor-TLR Cross-Talk Elicits Pro-Inflammatory Cytokine Production by Human M2 Macrophages
Scientists show that human M2 macrophages promote inflammation instead of suppressing inflammation on simultaneous exposure to complexed IgG and TLR ligands, as occurs in the context of diseases such as rheumatoid arthritis. [Nat Commun] Full Article
Selective Oral ROCK2 Inhibitor Down-Regulates IL-21 and IL-17 Secretion in Human T Cells via STAT3-Dependent Mechanism
The authors show that targeted rho-associated kinase 2 (ROCK2) inhibition down-regulates proinflammatory responses via concurrent regulation of STAT3/STAT5 phosphorylation and shifting Th17/Treg balance in human T cells with a minimal effect on the rest of the immune response. [Proc Natl Acad Sci USA]
Abstract
|
Full Article
|
Press Release
Tumor-Induced Senescent T Cells Promote the Secretion of Pro-Inflammatory Cytokines and Angiogenic Factors by Human Monocytes/Macrophages through a Mechanism that Involves Tim-3 and CD40L
Investigators report that tumor-induced senescent (TIS)-T cells may modulate monocyte activation. To gain insight into this interaction, CD4+ or CD8+TIS-T or control-T cells were co-incubated with autologous monocytes under inflammatory conditions. [Cell Death Dis] Full Article
C3d Adjuvant Effects Are Mediated through the Activation of C3d-Specific Autoreactive T Cells
C3d peptide sequences were previously synthesized and shown in vitro to bind multiple human leukocyte antigen (HLA)-DR alleles with high affinity, and induce interferon-γ responses in healthy donor peripheral blood mononuclear cells. Now investigators establish further correlations between HLA binding and HLA-specific lymphocyte reactions with select epitope clusters. [Immunol Cell Biol] Abstract
Glioblastoma Exosomes and IGF-1R/AS-ODN Are Immunogenic Stimuli in a Translational Research Immunotherapy Paradigm
In a pilot study, a vaccine consisting of Lucite diffusion chambers containing irradiated autologous tumor cells pre-treated with an antisense oligodeoxynucleotide directed against the insulin-like growth factor type 1 receptor was found to elicit positive clinical responses in 8/12 patients when implanted in the rectus sheath for 24 hours. Investigators make use of a murine glioma model and samples from glioblastoma patients in this second Phase I trial to investigate this novel therapeutic intervention more thoroughly. [Cancer Immunol Immunother]
Abstract
|
Press Release
Methylation of NKG2D Ligands Contributes to Immune System Evasion in Acute Myeloid Leukemia
Researchers demonstrate that DNA methylation can contribute to the absence of NKG2DL (natural killer group 2 member D ligand) expression during tumor progression. Treatment with demethylating agents restored the expression of NKG2DL on the cell surface of acute myeloid leukemia cells, leading to an enhanced recognition by NKG2D-expressing cells. [Genes Immun] Abstract
Dendritic Cell Reconstitution Is Associated with Relapse-Free Survival and Acute GvHD Severity in Children after Allogeneic Stem Cell Transplantation
The authors investigated the age- and sex-dependent immune reconstitution of myeloid and plasmacytoid DC in the peripheral blood of 45 children with leukemia or myelodysplastic syndrome after allo-SCT with regard to relapse, acute GvHD and relapse-free survival. [Bone Marrow Transplant] Abstract
Selective, Efficient Modulation of Activated CD4+ αβT Cells by the Novel Humanized Antibody GZ-αβTCR Targeting Human αβTCR
The novel humanized monoclonal antibody GZ-αβTCR, specific for the human αβT-cell receptor, was tested in vitro and in vivo for its specificity and efficacy to modulate the αβT-cell compartment. [Bone Marrow Transplant] Abstract
Subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News!
|
| | | REVIEWS |
Molecular Regulation of Effector and Memory T Cell Differentiation
The authors underscore progress in delineating the underlying pathways that control diversification in T cell responses but also reveal gaps in the knowledge, as well as the challenges that arise in the application of this knowledge to rationally elicit desired T cell responses through vaccination and immunotherapy. [Nat Immunol] Abstract
Visit our reviews page to see a complete list of reviews in the human immunology research field.
|
| | | SCIENCE NEWS |
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (Abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA)
Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT trial that investigated the use of Orencia plus MTX in biologic and MTX-naïve CCP-positive early moderate to severe RA patients. [Press release from Bristol-Myers Squibb Company discussing research presented at the American College of Rheumatology (ACR) 2014 Annual Meeting, Boston] Press Release
Merck Announces Positive Study Investigating the Use of KEYTRUDA® (Pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
Merck announced that a pre-specified analysis of investigational data from a pivotal Phase II study showed KEYTRUDA® substantially improved the primary endpoint of progression-free survival compared to chemotherapy in patients with ipilimumab-refractory advanced melanoma. [Press release from Merck & Co., Inc. discussing research presented at the Society of Melanoma Research (SMR) 2014 International Congress, Zurich] Press Release
Study Comparing Opdivo (Nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase III Trial
Bristol-Myers Squibb Company announced results from CheckMate-066, a Phase III randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine in patients with treatment naïve BRAF wild-type advanced melanoma. [Press release from Bristol-Myers Squibb Company discussing research presented at the Society of Melanoma Research (SMR) 2014 International Congress, Zurich] Press Release
Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase IIa Clinical Trial Data
Galena Biopharma, Inc. announced that data from the company’s Phase I/IIa trial of GALE-301, a folate binding protein-derived immunotherapy, was presented. [Press release from Galena Biopharma, Inc. discussing research presented at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, National Harbor] Press Release
Phase II Clinical Data Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals’ Bavituximab in Liver Cancer
Peregrine Pharmaceuticals, Inc. announced clinical and preclinical data related to the company’s immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab. [Press release from Peregrine Pharmaceuticals, Inc. discussing research presented at the Society for Immunotherapy of Cancer’s (SITC) 29th Annual Meeting, National Harbor] Press Release
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
|
|
